Document:

Exhibit 10(l)(xi)

RESTRICTED UNIT AWARD AGREEMENT

Pursuant to the

ALBANY INTERNATIONAL CORP.

2003 RESTRICTED STOCK UNIT PLAN

*  *  *  *  *

	Participant:	 	Daniel
 Halftermeyer
	Award Date:	 	August 28, 2018

Number of Restricted Units Awarded: 12,853

*  *  *  *  *

THIS AWARD AGREEMENT,
dated as of the Award Date specified above, is entered into by and between Albany International Corp. (the “Company”),
and the Participant specified above, pursuant to the Amended and Restated Albany International Corp. 2003 Restricted Stock Unit
Plan, as in effect and as amended from time to time (the “Plan”); and

 

WHEREAS, as
an incentive to encourage the Participant to remain in the employ of the Company and its subsidiaries by affording the Participant
a greater interest in the success of the Company and its subsidiaries, the Company desires to grant the Participant the Restricted
Units provided herein;

 

WHEREAS, the
Participant desires to obtain such Restricted Units on the terms and conditions provided for herein;

 

NOW, THEREFORE,
in consideration of the premises, the mutual covenants herein set forth and other good and valuable considerations receipt of which
is hereby acknowledged, the Company and the Participant agree as follows:

1.
               
Incorporation by Reference; Plan Document Receipt. Except as otherwise provided herein,
this Award Agreement is subject in all respects to the terms and provisions of the Plan (including, without limitation, any amendments
thereto adopted at any time and from time to time and which are expressly intended to apply to the grant of the Restricted Units
provided for herein), all of which terms and provisions are made a part of and incorporated in this Award Agreement as if they
were expressly set forth herein. Any capitalized term not defined in this Award Agreement shall have the same meaning as is ascribed
thereto in the Plan. The Participant hereby acknowledges receipt of a true copy of the Plan and that the Participant has read the
Plan carefully and fully understands its content. In the event of a conflict between the terms of this Award Agreement and the
terms of the Plan, the terms of the Plan shall control.

2.
               
Award of Restricted Units; Credit to Restricted Unit Account. Subject to the terms
hereof and the Plan, the Company hereby grants to the Participant, as of the Award Date specified above, the number of Restricted
Units specified above. The Company shall record such Restricted Units in the Participant’s Restricted Unit Account.

3.
               
Vesting. As permitted in Section 5.1 of the Plan, and subject to paragraph 6 below,
the following Vesting Dates shall apply with respect to the Restricted Units (including any additional Restricted Units credited
as Cash Dividend Equivalents with respect to such Restricted Units) awarded hereunder and shall supersede any contrary provision
in Section 5.1:

a.                   
One-third (33.3%) of such Restricted Units (including any additional Restricted Units credited
as Cash Dividend Equivalents with respect to such Restricted Units) shall vest on September 1, 2019.

b.                  
One-third (33.3%) of such Restricted Units (including any additional Restricted Units credited
as Cash Dividend Equivalents with respect to such Restricted Units) shall vest on September 1, 2020; and 

     

    	 

    

c.                   
The remaining one-third (33.3%) of such Restricted Units (including any additional Restricted
Units credited as Cash Dividend Equivalents with respect to such Restricted Units) shall vest on September 1, 2021, in each case,
subject to the Participant being employed with the Albany Group on such Vesting Date.

 

4.
               
Additional Special Vesting. The special vesting provisions set forth in Section 5.2
of the Plan shall apply to the Restricted Units (including any additional Restricted Units credited as Cash Dividend Equivalents
with respect to such Restricted Units) awarded hereunder. 

5.
                                       
Settlement; Payment Delay. Subject to Paragraph 6 below, the Restricted Units (including
any additional Restricted Units credited as Cash Dividend Equivalents with respect to such Restricted Units) credited to Participant’s
Restricted Unit Account pursuant to this Award Agreement shall be settled in accordance with the provisions of the Plan, including
without limitation Section 6.1 of the Plan. Notwithstanding any provision to the contrary, if, pursuant to the provisions of Section
409A of the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder (the “Code”), any
payment is required to be delayed as a result of the Participant being deemed to be a “specified employee” within the
meaning of that term under Section 409A(a)(2)(B) of the Code, then any such payments under the Plan shall not be made prior to
the earlier of (A) the expiration of the six month period measured from the date of the “separation from service” (as
such term is defined in Treasury Regulations issued under Section 409A of the Code) or (B) the date of the Participant’s
death. Upon the expiration of such period, all payments under the Plan delayed pursuant to this paragraph 6 shall be paid to the
Participant in a lump sum, and any remaining payments due under the Plan shall be paid or provided in accordance with the normal
payment dates specified for them herein. 

6.
                                       
Repayment/Clawback. It is the Company’s intent, through the Restricted Unit grant
contemplated herein, to incentivize Participant to voluntarily remain in its employ at least through September 1, 2021. Nevertheless,
Participant has expressly requested that the Restricted Units granted herein vest ratably as set forth in Paragraph 3, above. Therefore,
Participant expressly agrees that should his employment with the Company terminate prior to September 1, 2021 for any reason other
than death or disability, he shall repay to the Company fifty percent (50%) of all the moneys paid to him pursuant to this Award
Agreement through the date of termination. The amount to be repaid, if any, shall be considered a debt owed by Participant to the
Company, and not repayment of wages. Furthermore, in the event Participant becomes obligated to make a payment to the Company in
accordance with this Paragraph 6, Participant agrees to remit such payment within 30 days of termination and, to the extent permitted
by law, authorizes the Company to withhold from his last payment of wages (or any other amounts that the Company may owe Participant)
any portion of the obligations owed by Participant pursuant to this Paragraph 6.

7.
               
Amendment and Waiver. Neither this Award Agreement nor any provision hereof may be
amended, modified, changed, discharged, terminated or waived orally, by any course of dealing or purported course of dealing or
by any other means except (a) in the case of an amendment, modification, change or waiver that does not impair the rights of the
Participant with respect to outstanding Restricted Units or that is deemed by the Committee to be advisable to avoid the imposition
of any tax under Section 409A of the Code, by written notice to the Participant or (b) an agreement in writing signed by the Company
and the Participant. No such written notice of agreement shall extend to or affect any provision of this Award Agreement not expressly
amended, modified, changed, discharged, terminated or waived or impair any right consequent on such a provision. The waiver of
or failure to enforce any breach of this Award Agreement shall not be deemed to be a waiver of or acquiescence in any other breach
hereof.

8.
               
Notices. Any notice required or permitted under this Award Agreement shall be in writing
and shall be deemed properly given:

8.1 in the case
of notice to the Company, if delivered in person to the Secretary of the Company, or mailed to the Company to the attention of
the Secretary by registered mail (return receipt requested) at 216 Airport Drive, Rochester, New Hampshire, 03867, or at such other
address as the Company may from time to time hereafter designate by written notice to the Participant; and

8.2 in the case
of notice to the Participant, if delivered to him or her in person, or mailed to him or her by registered mail (return receipt
requested) at the last known residence address provided by Participant to the Company or at such other address as the Participant
may from time to time hereafter designate by written notice to the Company.

 

9.
               
Governing Law. This Award Agreement shall be governed by and construed in accordance
with the laws of the State of New York.

10.
             Binding
Agreement; Assignment. This Award Agreement shall inure to the benefit of, be binding upon, and be enforceable by the Company
and its successors and assigns. The Participant shall not assign any part of this Award Agreement without the prior express written
consent of the Company.

     

    	 

    

11.
             Counterparts.
This Award Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which
shall constitute one and the same instrument.

12.
             Headings.
The titles and headings of the various sections of this Award Agreement have been inserted for convenience of reference only and
shall not be deemed to be a part of this Award Agreement.

13.
             Further
Assurances. Each party hereto shall do and perform (or shall cause to be done and performed) all such further acts and shall
execute and deliver all such other agreements, certificates, instruments and documents as any other party hereto reasonably may
request in order to carry out the intent and accomplish the purposes of this Award Agreement and the Plan and the consummation
of the transactions contemplated thereunder.

14.
             Severability.
The invalidity or unenforceability of any provisions of this Award Agreement in any jurisdiction shall not affect the validity,
legality or enforceability of the remainder of this Award Agreement in such jurisdiction or the validity, legality or enforceability
of any provision of this Award Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties
hereunder shall be enforceable to the fullest extent permitted by law.

15.
             Acceptance
of Restricted Units. Unless, within 45 days following the date of this Award Agreement, the Company has received written notice
from the Participant rejecting the Restricted Units, this Award Agreement shall be deemed to have been accepted by the Participant
and shall constitute a legal and binding agreement between the Participant and the Company.

IN WITNESS WHEREOF,
the Company has duly executed this Award Agreement as of the Award Date specified above.

 

ALBANY INTERNATIONAL
CORP.

 

___________________________

Name:

Title:

 

 

/s/Daniel
A. Halftermeyer 

Daniel A. HalftermeyerEX-4.1

 Exhibit 4.1 

Warrant Number              

THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS
(1) SUCH TRANSACTION IS MADE PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT AND THE APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OR (2) THE COMPANY IS PROVIDED WITH AN OPINION OF COUNSEL,
SATISFACTORY TO THE COMPANY, STATING THAT SUCH TRANSACTION IS IN COMPLIANCE WITH EXEMPTIONS FROM REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS. NO TRANSFER OF ANY INTEREST IN THIS WARRANT OR THE SECURITIES ISSUABLE UPON
EXERCISE HEREOF MAY BE EFFECTED WITHOUT FIRST SURRENDERING THIS WARRANT OR SUCH SECURITIES, AS THE CASE MAY BE, TO THE COMPANY OR ITS TRANSFER AGENT, IF ANY. 

Warrant to Purchase 
 Shares of

 Common Stock 
 As Herein
Described 
                     
        , 201     
 WARRANT TO PURCHASE COMMON STOCK OF

 CYTODYN INC. 

This is to certify that, for value received,
                        , or a proper assignee (the “Holder”), is entitled to purchase up to
                    shares (“Warrant Shares”) of common stock, $0.001 par value per share (the “Common Stock”), of CytoDyn Inc.,
a Delaware corporation (the “Company”), subject to the provisions of this Warrant. This Warrant shall be exercisable at seventy-five ($0.75) per share (the “Exercise Price”). This Warrant also is subject to the following terms
and conditions: 
 1. Exercise and Payment; Exchange. 

(a) This Warrant may be exercised in whole or in part at any time from and after the date hereof (the “Commencement Date”) through
5:00 p.m., Pacific time, on the date that is five (5) years following the Commencement Date (the “Expiration Date”), at which time this Warrant shall expire and become void, but if such date is a day on which federal or state
chartered banking institutions located in the State of New York are authorized to close, then on the next succeeding day which shall not be such a day. Exercise shall be by presentation and surrender to the Company, or at the office of any transfer
agent designated by the Company (the 

 
“Transfer Agent”), of (i) this Warrant, (ii) the attached exercise form properly executed, and (iii) a certified or official bank check for the Exercise Price for the
number of Warrant Shares specified in the exercise form. If this Warrant is exercised in part only, the Company or the Transfer Agent shall, upon surrender of the Warrant, execute and deliver a new Warrant evidencing the rights of the Holder to
purchase the remaining number of Warrant Shares purchasable hereunder. Upon receipt by the Company of this Warrant, the properly executed exercise form, and payment as aforesaid, the Holder shall be deemed to be the holder of record of the Common
Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such Warrant Shares shall not then be actually delivered to the Holder. Under no circumstance
shall the Company be required to make any cash payments or net cash settlement to the Holder in lieu of delivery of the Warrant Shares. 

(b) Conditions to Exercise or Exchange. The restrictions in Section 7 shall apply, to the extent applicable by their terms, to any
exercise or exchange of this Warrant permitted by this Section 1. 
 2. Reservation of Shares. The Company shall, at all times
until the expiration of this Warrant, reserve for issuance and delivery upon exercise of this Warrant the number of Warrant Shares which shall be required for issuance and delivery upon exercise of this Warrant. 

3. Fractional Interests. The Company shall not issue any fractional shares or scrip representing fractional shares upon the exercise or
exchange of this Warrant. With respect to any fraction of a share resulting from the exercise or exchange hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the current fair market value per share of
Common Stock, determined as follows: 
 (a) If the Common Stock is listed on a national securities exchange or admitted to unlisted trading
privileges on such an exchange, the current fair market value shall be the last reported sale price of the Common Stock on such exchange on the last business day prior to the date of exercise of this Warrant or if no such sale is made on such day,
the mean of the closing bid and asked prices for such day on such exchange; 
 (b) If the Common Stock is not so listed or admitted to
unlisted trading privileges on a national securities exchange, the current fair market value shall be the mean of the last bid and asked prices reported on the last business day prior to the date of the exercise of this Warrant by the OTC Markets
Group, Inc.; or 
 (c) If the Common Stock is not so listed or admitted to unlisted trading privileges on a national securities exchange and
bid and asked prices are not so reported, the current fair market value shall be an amount, not less than book value, determined in such reasonable manner as may be prescribed by the Company in good faith. 

4. No Rights as Shareholder. This Warrant shall not entitle the Holder to any rights as a shareholder of the Company, either at law or
in equity. The rights of the Holder are limited to those expressed in this Warrant and are not enforceable against the Company except to the extent set forth herein. 

  
 2 

 5. Adjustments in Number and Exercise Price of Warrant Shares. 

5.1 The number of shares of Common Stock for which this Warrant may be exercised and the Exercise Price therefor shall be subject to adjustment
as follows: 
 (a) If the Company is recapitalized through the subdivision or combination of its outstanding shares of Common Stock into a
larger or smaller number of shares, the number of Warrant Shares shall be increased or reduced, as of the record date for such recapitalization, in the same proportion as the increase or decrease in the outstanding shares of Common Stock, and the
Exercise Price shall be adjusted so that the aggregate amount payable for the purchase of all of the Warrant Shares issuable hereunder immediately after the record date for such recapitalization shall equal the aggregate amount so payable
immediately before such record date. 
 (b) If the Company declares a dividend on Common Stock payable in Common Stock or securities
convertible into Common Stock, the number of shares of Common Stock for which this Warrant may be exercised shall be increased as of the record date for determining which holders of Common Stock shall be entitled to receive such dividend, in
proportion to the increase in the number of outstanding shares (and shares of Common Stock issuable upon conversion of all such securities convertible into Common Stock) of Common Stock as a result of such dividend, and the Exercise Price shall be
adjusted so that the aggregate amount payable for the purchase of all the Warrant Shares issuable hereunder immediately after the record date for such dividend shall equal the aggregate amount so payable immediately before such record date. 

(c) If the Company distributes to holders of its Common Stock, other than as part of its dissolution or liquidation or the winding up of its
affairs, any evidence of indebtedness or any of its assets (other than cash, Common Stock or securities convertible into Common Stock), the Company shall give written notice to the Holder of any such distribution at least fifteen (15) days
prior to the proposed record date in order to permit the Holder to exercise this Warrant on or before the record date. There shall be no adjustment in the number of shares of Common Stock for which this Warrant may be exercised, or in the Exercise
Price, by virtue of any such distribution. 
 (d) If the Company offers rights or warrants to the holders of Common Stock which entitle them
to subscribe to or purchase additional Common Stock or securities convertible into Common Stock, the Company shall give written notice of any such proposed offering to the Holder at least fifteen (15) days prior to the proposed record date in
order to permit the Holder to exercise this Warrant on or before such record date. There shall be no adjustment in the number of shares of Common Stock for which this Warrant may be exercised, or in the Exercise Price, by virtue of any such
distribution. 
 (e) If the event, as a result of which an adjustment is made under paragraph (a) or (b) above, does not occur, then
any adjustments in the Exercise Price or number of shares issuable that were made in accordance with such paragraph (a) or (b) shall be adjusted to the Exercise Price and number of shares as were in effect immediately prior to the record date
for such event. 

  
 3 

 5.2 In the event of any reorganization or reclassification of the outstanding shares of
Common Stock (other than a change in par value or from no par value to par value, or from par value to no par value, or as a result of a subdivision or combination) or in the event of any consolidation or merger of the Company with another entity
after which the Company is not the surviving entity, at any time prior to the expiration of this Warrant, upon subsequent exercise of this Warrant the Holder shall have the right to receive the same kind and number of shares of common stock and
other securities, cash or other property as would have been distributed to the Holder upon such reorganization, reclassification, consolidation or merger had the Holder exercised this Warrant immediately prior to such reorganization,
reclassification, consolidation or merger, appropriately adjusted for any subsequent event described in this Section 5. The Holder shall pay upon such exercise the Exercise Price that otherwise would have been payable pursuant to the terms of
this Warrant. If any such reorganization, reclassification, consolidation or merger results in a cash distribution in excess of the then applicable Exercise Price, the Holder may, at the Holder’s option, exercise this Warrant without making
payment of the Exercise Price, and in such case the Company shall, upon distribution to the Holder, consider the Exercise Price to have been paid in full, and in making settlement to the Holder, shall deduct an amount equal to the Exercise Price
from the amount payable to the Holder. In the event of any such reorganization, merger or consolidation, the corporation formed by such consolidation or merger or the corporation which shall have acquired the assets of the Company shall execute and
deliver a supplement hereto to the foregoing effect, which supplement shall also provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided in this Warrant. 

5.3 If the Company shall, at any time before the expiration of this Warrant, dissolve, liquidate or wind up its affairs, the Holder shall have
the right to receive upon exercise of this Warrant, in lieu of the shares of Common Stock of the Company that the Holder otherwise would have been entitled to receive, the same kind and amount of assets as would have been issued, distributed or paid
to the Holder upon any such dissolution, liquidation or winding up with respect to such Common Stock receivable upon exercise of this Warrant on the date for determining those entitled to receive any such distribution. If any such dissolution,
liquidation or winding up results in any cash distribution in excess of the Exercise Price provided by this Warrant, the Holder may, at the Holder’s option, exercise this Warrant without making payment of the Exercise Price and, in such case,
the Company shall, upon distribution to the Holder, consider the Exercise Price to have been paid in full and, in making settlement to the Holder, shall deduct an amount equal to the Exercise Price from the amount payable to the Holder. 

6. Notices to Holder. So long as this Warrant shall be outstanding (a) if the Company shall pay any dividends or make any
distribution upon the Common Stock otherwise than in cash or (b) if the Company shall offer generally to the holders of Common Stock the right to subscribe to or purchase any shares of any class of Common Stock or securities convertible into
Common Stock or any similar rights or (c) if there shall be any capital reorganization of the Company in which the Company is not the surviving entity, recapitalization of the capital stock of the Company, consolidation or merger of the Company
with or into another corporation, sale, lease or other transfer of all or substantially all of the property and assets of the Company, or voluntary or involuntary dissolution, liquidation or winding up of the Company, then in such event, the Company
shall cause to be mailed to the 

  
 4 

 
Holder, at least thirty (30) days prior to the relevant date described below (or such shorter period as is reasonably possible if thirty (30) days is not reasonably possible), a notice
containing a description of the proposed action and stating the date or expected date on which a record of the Company’s shareholders is to be taken for the purpose of any such dividend, distribution of rights, or such reclassification,
reorganization, consolidation, merger, conveyance, lease or transfer, dissolution, liquidation or winding up is to take place and the date or expected date, if any is to be fixed, as of which the holders of Common Stock of record shall be entitled
to exchange their shares of Common Stock for securities or other property deliverable upon such event. 
 7. Transfer, Exercise, Exchange,
Assignment or Loss of Warrant, Warrant Shares or Other Securities. 
 7.1 This Warrant may be transferred, exercised, exchanged or
assigned (“transferred”), in whole or in part, subject to the following restrictions. This Warrant and the Warrant Shares or any other securities (“Other Securities”) received upon exercise of this Warrant shall be subject to
restrictions on transferability until registered under the Securities Act of 1933, as amended (the “Securities Act”), unless an exemption from registration is available. Until this Warrant and the Warrant Shares or Other Securities are so
registered, this Warrant and any certificate for Warrant Shares or Other Securities issued or issuable upon exercise of this Warrant shall contain a legend on the face thereof, in form and substance satisfactory to counsel for the Company, stating
that this Warrant the Warrant Shares or Other Securities may not be sold, transferred or otherwise disposed of unless, in the opinion of counsel satisfactory to the Company, which may be counsel to the Company, that this Warrant, the Warrant Shares
or Other Securities may be transferred without such registration. This Warrant and the Warrant Shares or Other Securities may also be subject to restrictions on transferability under applicable state securities or blue sky laws. Until this Warrant
and the Warrant Shares or Other Securities are registered under the Securities Act, the Holder shall reimburse the Company for its expenses, including attorneys’ fees, incurred in connection with any transfer or assignment, in whole or in part,
of this Warrant or any Warrant Shares or Other Securities. 
 7.2 Until this Warrant, the Warrant Shares or other Securities are registered
under the Securities Act, the Company may require, as a condition of transfer of this Warrant, the Warrant Shares, or Other Securities, that the transferee (who may be the Holder in the case of an exercise or exchange) represent that such transferee
is an “accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act and that the securities being transferred are being acquired for investment purposes and for the transferee’s own account and not with
a view to or for sale in connection with any distribution of the security. 
 7.3 Any transfer permitted hereunder shall be made by surrender
of this Warrant to the Company or to the Transfer Agent at its offices with a duly executed request to transfer the Warrant, which shall provide adequate information to effect such transfer and shall be accompanied by funds sufficient to pay any
transfer taxes applicable. Upon satisfaction of all transfer conditions, the Company or Transfer Agent shall, without charge, execute and deliver a new Warrant in the name of the transferee named in such transfer request, and this Warrant promptly
shall be cancelled. 

  
 5 

 7.4 Upon receipt by the Company of evidence satisfactory to it of loss, theft, destruction
or mutilation of this Warrant and, in the case of loss, theft or destruction, of reasonable satisfactory indemnification, or, in the case of mutilation, upon surrender of this Warrant, the Company will execute and deliver, or instruct the Transfer
Agent to execute and deliver, a new Warrant of like tenor and date, any such lost, stolen or destroyed Warrant thereupon shall become void. 

8. Representations and Warranties of the Holder. The Holder hereby represents and warrants to the Company with respect to the issuance
of the Warrant as follows: 
 8.1 Experience. The Holder has substantial experience in evaluating and investing in securities
in companies similar to the Company so that such Holder is capable of evaluating the merits and risks of such Holder’s investment in the Company and has the capacity to protect such Holder’s own interests. 

8.2 Investment. The Holder is acquiring this Warrant (and the Warrant Shares issuable upon exercise of this Warrant) for investment for
such Holder’s own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof. The Holder understands that this Warrant (and the Warrant Shares issuable upon exercise of the Warrant)
have not been, and will not be, registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and
the accuracy of such Holder’s representations as expressed herein. 
 8.3 Held Indefinitely. The Holder acknowledges that this
Warrant (and the Warrant Shares issuable upon exercise of this Warrant) must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available. 

8.4 Accredited Holder. The Holder is an “accredited investor” within the meaning of Rule 501 of Regulation D under the
Securities Act. 
 8.5 Legends. The Holder understands and acknowledges that the certificate(s) evidencing the securities issued by
the Company will be imprinted with a restrictive legend as referenced in Section 7.1 above. 
 8.6 Access to Data. The Holder has
had an opportunity to discuss the Company’s business, management, and financial affairs with the Company’s management and the opportunity to review the Company’s facilities and business plans. The Holder has also had an opportunity to
ask questions of officers of the Company, which questions were answered to its satisfaction. 
 8.7 Authorization. This Warrant
and the agreements contemplated hereby, when executed and delivered by the Holder, will constitute a valid and legally binding obligation of the Holder, enforceable in accordance with their respective terms. 

  
 6 

 8.8 Brokers or Finders. The Company has not incurred, and will not incur, directly or
indirectly, as a result of any action taken by such Holder, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with this Warrant or any transaction contemplated hereby. 

9. Notices. All notices, requests, demands or other communications hereunder shall be in writing and shall be deemed to have been duly
given, if delivered in person or mailed, certified, return-receipt requested, postage prepaid to the address previously provided to the other party, or sent by fax or email (to the extent stated below). Either party hereto may from time to time, by
written notice to the other party, designate a different address. If any notice or other document is sent by certified or registered mail, return receipt requested, postage prepaid, properly addressed as aforementioned, the same shall be deemed
delivered seventy-two (72) hours after mailing thereof. If any notice is sent by fax or email, it will be deemed to have been delivered on the date the fax or email thereof is actually received, provided
the original thereof is sent by certified mail, in the manner set forth above, within twenty-four (24) hours after the fax or email is sent. 

10. Amendment. Any provision of this Warrant may be amended or the observance thereof may be waived (either generally or in a particular
instance and either retroactively or prospectively), only with the mutual written consent of the Company and the Holder. 
 11. Governing
Law. This Warrant shall be governed by and construed in accordance with the laws of the State of New York. 
 [Signature page
follows.] 

  
 7 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. 
  

			
	CYTODYN INC.

 
			
		
	By:	 	 

 
			
	Name: Michael D. Mulholland
	Title: Chief Financial Officer

 [Signature Page to Common Stock Purchase Warrant] 

 FORM OF EXERCISE 

To be executed upon exercise of Warrant 

(please print) 
 The
undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Number             certificate,
to                     shares of common stock, $0.001 par value per share (“Common Stock”) of CytoDyn Inc. (the “Company”) and
herewith tenders payment for such shares of Common Stock to the order of the Company the amount of $0.75 per share in accordance with the terms hereof. The undersigned requests that a certificate for such shares of Common Stock be registered in the
name of                                     whose address is
                                         
       . If said number of shares of Common Stock is less than all of the shares of Common Stock purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the remaining balance of
the shares of Common Stock be registered in the name of
                                        , whose
address is
                                         
               , and that such Warrant Certificate be delivered
to                            , whose address is
                                         
   . 
 Representations of the undersigned. 
  

	 	a)	 The undersigned acknowledges that the undersigned has received, read and understood the Warrant and agrees to
abide by and be bound by its terms and conditions. 

  

	 	b)	 (i) The undersigned has such knowledge and experience in business and financial matters that the undersigned is
capable of evaluating the Company and the proposed activities thereof, and the risks and merits of this prospective investment. 

☐  YES    ☐  NO 
  

	 	(ii)	 If “No”, the undersigned is represented by a “purchaser representative,” as that term is
defined in the Securities Act of 1933, as amended (the “Securities Act”) and Regulation D thereunder. 

☐  YES    ☐  NO 
  

	 	c)	 (i) The undersigned is an “accredited investor,” as that term is defined in the Securities Act and
Rule 501 of Regulation D thereunder. 

 ☐  YES    ☐  NO 

(ii) If “Yes,” the undersigned comes within the following category of that definition (check one and complete the blanks as
applicable): 
  

	 	☐	 1. The undersigned is a natural person whose present net worth (or whose joint net worth with his or her
spouse), excluding the value of the undersigned’s primary residence, exceeds $1,000,000. For purposes of calculating the undersigned’s present net worth, the undersigned has

  
 1 

	 	
included the following as liabilities: (i) any indebtedness that is secured by the undersigned’s primary residence in excess of the estimated fair market value of the undersigned’s
primary residence at the time of the sale of the shares, and (ii) any incremental debt secured by the undersigned’s primary residence that was incurred in the 60 days before the sale of the shares, other than as a result of the acquisition
of the undersigned’s primary residence. 

  

	 	☐	 2. The undersigned is a natural person who had individual income in excess of $200,000 in each of the last two
years or joint income with the undersigned’s spouse in excess of $300,000 during such two years, and the undersigned reasonably expects to have the same income level in the current year. 

 

	 	☐	 3. The undersigned is an officer or director of the Company. 

 

	 	☐	 4. The undersigned is a corporation or partnership not formed for the specific purpose of acquiring the
securities offered, with total assets in excess of $5,000,000. 

  

	 	☐	 5. The undersigned is a trust with total assets in excess of $5,000,000 whose purchase is directed by a person
with such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of the prospective investment. 

 

	 	☐	 6. The undersigned is an entity, all of whose equity owners are accredited investors under paragraphs 1, 2, 3,
4 or 5, above. 

  

	 	d)	 The undersigned understands that the shares purchased hereunder have not been registered under the Securities
Act, in reliance upon the exemption from the registration requirements under the Securities Act pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D thereunder; and, therefore, that the undersigned must bear the
economic risk of the investment for an indefinite period of time since the securities cannot be sold, transferred or assigned to any person or entity without compliance with the provisions of the Securities Act. 

 

			
	Submitted by:	  	Accepted by CytoDyn Inc.:
		
	By:                                     
                                         
              	  	By:                                     
                                         
      
	Date:                                     
                                         
           	  	Date:                                     
                                         
   
	SS/Tax
ID:                                        
                                        	  	Tax
ID:                                        
                                     
	Telephone:                                    
                                         
   	  	
	Email:                                     
                                         
          	  	

 (Signature must conform in all respects to name of holder as specified on the face of the Warrant Certificate.) 

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]